Bulk anti-Human EGFR antibody (EGFR.1) - Low Endotoxin

Bulk anti-Human EGFR antibody (EGFR.1) - Low Endotoxin

Catalog Number:
A001437209ICH
Mfr. No.:
ICH1021
Price:
$680
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Specificity: Anti-EGFR In Vivo Antibody - Low Endotoxin (EGFR.1) recognizes the (Mr 170 kDa) extracellular domain of the epidermal growth factor receptor on many cell surfaces. The EGFR mediates the initial response of cells to EGF. It has an extracellular region which binds EGF and an intracellular region which exhibits tyrosine kinase activity. The receptor phosphorylates a number of protein substrates in addition to mediating autophosphorylation
          Isotype Control: Mouse IgG2b Isotype Control for In Vivo - Low Endotoxin [MPC-11] (ICH2250)
          Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method
          Aggregation: Aggregation level ≤ 5%

          Please contact us at for specific academic pricing.

          Background

          The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor A (TGFA) (note, a full list of the ligands able to activate EGFR and other members of the ErbB family is given in the ErbB article). ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer - although there is some evidence that preformed inactive dimers may also exist before ligand binding. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.

      • Properties
        • Host
          mouse
          Isotype
          IgG2b kappa
          Reactivity
          human
          Clone
          EGFR.1
          Immunogen
          A431 cultured cells
          Purification
          >95% by SDS-PAGE and HPLC
          Formulation
          0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
          Storage
          anti-EGFR In Vivo Antibody - Low Endotoxin (EGFR.1) is stable when stored at 2-8°C. Do not freeze.
          Molecular Weight
          1.0 - 5.0 mg/ml
          Regulatory Status
          Each investigator should determine their own optimal working dilution for specific applications.

          * Products are for research use only. Not for use in diagnostic or therapeutic procedures.

      • Applications
        • Application
          Flow Cytometry; Immunocytochemistry; Immunofluorescence; IHC (frozen); Immunoprecipitation; Neutralization; IP-Mass Spectrometry

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.